摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-(2,4'-bithiazol-2'-yl)-3-(prop-2-ynyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one | 1259488-61-3

中文名称
——
中文别名
——
英文名称
8-(2,4'-bithiazol-2'-yl)-3-(prop-2-ynyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one
英文别名
3-prop-2-ynyl-8-[4-(1,3-thiazol-2-yl)-1,3-thiazol-2-yl]imidazo[5,1-d][1,2,3,5]tetrazin-4-one
8-(2,4'-bithiazol-2'-yl)-3-(prop-2-ynyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one化学式
CAS
1259488-61-3
化学式
C13H7N7OS2
mdl
——
分子量
341.377
InChiKey
RITDBPPZOXQGDB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    23
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    145
  • 氢给体数:
    0
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use
    申请人:Hummersone Marc Geoffery
    公开号:US20120083513A1
    公开(公告)日:2012-04-05
    The present invention pertains generally to the field of therapeutic compounds, and more specifically to 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds of the following formula, wherein -A and —B are as defined herein (collectively referred to herein as 38TM compounds): The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.
    本发明涉及治疗化合物领域,更具体地涉及以下式子的3-取代-8-取代-3H-咪唑[5,1-d][1,2,3,5]四唑-4-酮化合物,其中-A和—B在此定义(统称为38TM化合物):本发明还涉及包含这种化合物的制药组合物,以及在体内外使用这种化合物和组合物来抑制细胞增殖,治疗增殖性疾病如癌症等,以及制备这种化合物的方法。
  • 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use
    申请人:Hummersone Marc Geoffery
    公开号:US09024018B2
    公开(公告)日:2015-05-05
    The present invention pertains generally to the field of therapeutic compounds, and more specifically to 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds of the following formula, wherein -A and —B are as defined herein (collectively referred to herein as 38TM compounds): The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.
    本发明涉及治疗化合物领域,更具体地涉及以下式子的3-取代-8-取代-3H-咪唑[5,1-d][1,2,3,5]四唑-4-酮化合物(统称为38TM化合物),其中-A和-B如本文所定义。本发明还涉及包括此类化合物的制药组合物以及使用此类化合物和组合物在体外和体内抑制细胞增殖,治疗增殖性疾病如癌症等的用途,以及制备此类化合物的方法。
  • 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE
    申请人:Pharminox Limited
    公开号:EP2445915B1
    公开(公告)日:2016-04-20
  • US9024018B2
    申请人:——
    公开号:US9024018B2
    公开(公告)日:2015-05-05
  • [EN] 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS 3H-IMIDAZO[5,1-D][1,2,3,5-TÉTRAZIN-4-ONE 3-SUBSTITUÉS-8-SUBSTITUÉS ET LEUR UTILISATION
    申请人:PHARMINOX LTD
    公开号:WO2010149968A1
    公开(公告)日:2010-12-29
    The present invention pertains generally to the field of therapeutic compounds, and more specifically to 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds of the following formula, wherein -A and -B are as defined herein (collectively referred to herein as 38TM compounds): (1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.
    本发明一般涉及治疗化合物领域,更具体地涉及以下公式的3-取代-8-取代-3H-咪唑[5,1-d][1,2,3,5]四唑-4-酮化合物,其中-A和-B如本文所定义(统称为38TM化合物):(1)。本发明还涉及包含这种化合物的药物组合物,以及利用这种化合物和组合物在体外和体内抑制细胞增殖,治疗增生性疾病如癌症等的用途,以及制备这种化合物的方法。
查看更多

同类化合物

米托唑胺 氰基替莫唑胺 替莫唑胺 N-[4-(2-氟苯甲酰)-1,3-二甲基-1H-吡唑-5-基]-N-甲基苯酰胺 3-(2H3)甲基-4-氧代-3,4-二氢咪唑并[5,1-d][1,2,3,5]四嗪-8-甲酰胺 3-(2-氯乙基)-N-甲基-4-氧代-3,4-二氢咪唑并[5,1-d][1,2,3,5]四嗪-8-甲酰胺 3-(2-氯乙基)-N,N-二甲基-4-氧代-3,4-二氢咪唑并[5,1-d][1,2,3,5]四嗪-8-甲酰胺 3-(2-氯乙基)-4-氧代-3H-咪唑并(5,1-d)-1,2,3,5-四嗪-8-羧酸 3,4-二氢-3-甲基-4-氧代咪唑并[5,1-D]-1,2,3,5-四嗪-8-甲酰胺酸 3-cyclohexyl-8-(pyrrolidinocarbonyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-cyclohexyl-8-(piperidinocarbonyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-cyclohexyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazin-8-N-methylcarboxamide ethyl 3-cyclohexyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate 3-cyclohexyl-8-(morpholinocarbonyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one S-n-butyl 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carbothioate 3-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(isopropylthio)-7-phenylimidazo[1,2-b][1,2,4,5]tetrazine 8-(morpholinocarbonyl)-3-(p-tolyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 4-oxo-3-(p-tolyl)imidazo[5,1-d][1,2,3,5]tetrazin-8-N-methylcarboxamide ethyl 4-oxo-3-(p-tolyl)imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate 8-(piperidinocarbonyl)-3-(p-tolyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3,8-dimethylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 8-acetyl-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-(4-methylimidazol-1-yl)imidazo[1,2-b][1,2,4,5]tetrazin 3-methyl-4-oxo-N-(sulfamoyloxy)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 3-methyl-4-oxo-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide N,N,3-trimethyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide methyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbimidothioate hydroiodide N,3-dimethyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide n-octyl 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylate 3-[2-(2-{2-[2-(dimethylamino)ethylcarbamoyl]-1-methylimidazol-4-ylcarbamoyl}-1-methylimidazol-4-ylcarbamoyl)-1-methylimidazol-4-yl]-3,4-dihydro-3-methyl-4-oxoimdazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 3-(5-{5-[2-(dimethylamino)ethylcarbamoyl]-1-methyl-pyrrol-3-ylcarbamoyl}-1-methylpyrrol-3-yl)-3,4-dihydro-3-methyl-4-oxoimdazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide hexyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate n-butyl 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylate 3-(2-{2-[2-(dimethylamino)ethylcarbamoyl]-1-methylimidazol-4-ylcarbamoyl}-1-methylimidazol-4-yl)-3,4-dihydro-3-methyl-4-oxoimdazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 3-{2-[2-(dimethylamino)ethylcarbamoyl]-1-methylimidazol-4-yl}-3,4-dihydro-3-methyl-4-oxoimdazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 8-carbamoyl-3-(2-trimethylsilylethoxy)methylimidazo<5,1-d>-1,2,3,5-tetrazin-4(3H)-one nor-temozolomide ethyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate 8-carbamoyl-3-trimethylsilylmethylimidazo<5,1-d>-1,2,3,5-tetrazin-4(3H)-one Temozolomide hydrochloride methyl 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylate [3-N-11C,13C-methyl]temozolomide [4-11C-carbonyl]temozolomide [3-N-11C-methyl]temozolomide N-(2,2-dimethoxyethyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboximidamide hydroiodide 3-(p-chlorophenyl)-8-(piperidinocarbonyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 8-(morpholinocarbonyl)-3-phenylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(propylthio)imidazo[1,2-b][1,2,4,5]tetrazine Imidazo[5,1-d][1,2,3,5]tetrazine 3-(2-(N-(4-fluorophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-imidazo[1,5-d][1,2,3,5]tetrazine-8-carboxamide